




RealRate

PHARMACEUTICAL 2018

DMK Pharmaceuticals Corp
Rank 141 of 332



The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 68% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 297%, being 45% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	21,462
Cost of Goods Sold	0
Intangible Assets	23,327
Liabilities, Current	8,788
Liabilities, Non-Current	0
Other Assets	55
Other Compr. Net Income	0
Other Expenses	7,177
Other Liabilities	3,068
Other Net Income	-1,089
Other Revenues	13,073
Property and Equipment	6,560
Research and Development	7,527
Selling, General and Administrative Expense	22,819

Output Variable	Value in 1000 USD
Assets	51,403
Liabilities	11,856
Expenses	37,523
Revenues	13,073
Stockholders Equity	39,547
Net Income	-25,539
Comprehensive Net Income	-25,539
BaseVar	57,472
ECR before LimitedLiability	192%
Economic Capital Ratio	297%